BioAge Labs vs Pliant Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage biotech targeting metabolic aging for obesity and muscle-wasting disorders. IPO Sep 2024 (Nasdaq: BIOA); $198M raised; lead program azelaprag discontinued; pivoting to NLRP3 inhibitors.
About
BioAge Labs is a clinical-stage biopharmaceutical company that harnesses the biology of human aging to discover novel targets and therapies for metabolic diseases. The company went public on the Nasdaq Global Select Market in September 2024 under the ticker BIOA, raising $198M. Its lead program, azelaprag — an oral APJ agonist — was discontinued in January 2025 after the Phase 2 STRIDES obesity trial observed liver transaminitis in a subset of patients. BioAge has since pivoted its APJ program to next-generation oral and parenteral agonists targeting 2026 IND submissions, while advancing BGE-102, a brain-penetrant NLRP3 inhibitor development candidate with potential best-in-class CNS and metabolic applications. The company continues to leverage its proprietary human aging database to identify and validate novel drug targets.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
About
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
BioAge Labs vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.